GB202108761D0 - Ocular disorders - Google Patents

Ocular disorders

Info

Publication number
GB202108761D0
GB202108761D0 GBGB2108761.4A GB202108761A GB202108761D0 GB 202108761 D0 GB202108761 D0 GB 202108761D0 GB 202108761 A GB202108761 A GB 202108761A GB 202108761 D0 GB202108761 D0 GB 202108761D0
Authority
GB
United Kingdom
Prior art keywords
ocular disorders
ocular
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108761.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ikarovec Ltd
Original Assignee
Ikarovec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikarovec Ltd filed Critical Ikarovec Ltd
Priority to GBGB2108761.4A priority Critical patent/GB202108761D0/en
Publication of GB202108761D0 publication Critical patent/GB202108761D0/en
Priority to PCT/GB2022/051540 priority patent/WO2022263845A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
GBGB2108761.4A 2021-06-18 2021-06-18 Ocular disorders Ceased GB202108761D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2108761.4A GB202108761D0 (en) 2021-06-18 2021-06-18 Ocular disorders
PCT/GB2022/051540 WO2022263845A1 (en) 2021-06-18 2022-06-17 Ocular disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108761.4A GB202108761D0 (en) 2021-06-18 2021-06-18 Ocular disorders

Publications (1)

Publication Number Publication Date
GB202108761D0 true GB202108761D0 (en) 2021-08-04

Family

ID=77050544

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108761.4A Ceased GB202108761D0 (en) 2021-06-18 2021-06-18 Ocular disorders

Country Status (2)

Country Link
GB (1) GB202108761D0 (en)
WO (1) WO2022263845A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359464A1 (en) * 2001-11-30 2003-06-17 Genvec, Inc. Angiopioetin related factors
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
CA2581769C (en) 2004-09-28 2014-03-11 Genexel-Sein, Inc. Methods of using chimeric coiled-coil molecule
DE102004063619A1 (en) 2004-12-27 2006-07-06 Cfs Kempten Gmbh Shrinkable multilayer film with a release layer
EP2168979A1 (en) * 2008-09-23 2010-03-31 Rheinische Friedrich-Wilhelms-Universität Bonn Method for isolating neural cells with tenascin-R connections
WO2016069950A2 (en) * 2014-10-29 2016-05-06 University Of Utah Research Foundation Methods of treating hypoxia-associated optical conditions with cartilage oligo matrix protein-angiopoietin 1 (comp-ang1)

Also Published As

Publication number Publication date
WO2022263845A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
IL287280A (en) Compounds and methods for the treatment of ocular disorders
CA197291S (en) Sunglasses
GB2589698B (en) Ocular prosthesis
EP3566055A4 (en) Methods for the treatment of neurological disorders
IL287264A (en) Compounds and methods for the treatment of ocular disorders
IL268946A (en) Gene therapy for ocular disorders
PL3653183T3 (en) Ocular insert
IL286311A (en) Eyelid speculum
EP3638316A4 (en) Gene therapy for ocular disorders
EP3634986A4 (en) Gene therapy for ocular disorders
SG11202107475PA (en) Ophthalmological lens
GB202108761D0 (en) Ocular disorders
IL289221A (en) Compounds for treatment of eye disorders
EP4040991A4 (en) Treatment for gastrointestinal disorders
IL309393A (en) Retinal disorders
IL309392A (en) Retinal disorders
GB202108756D0 (en) Retinal disorders
GB202108760D0 (en) Retinal disorders
GB202108759D0 (en) Retinal disorders
GB201916506D0 (en) Corneal tissue
GB202204230D0 (en) Retinal Disorders
GB202204234D0 (en) Retinal Disorders
GB202204231D0 (en) Retinal Disorders
GB201820021D0 (en) Ocular hydrogel compositions
EP3658217A4 (en) Treatment of eye disorders

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)